Xtant Medical Holdings, Inc. (XTNT) Earnings Call Analysis

AMEX · Healthcare · Medical Devices

8/25

Growth 2 Margin 0 Expansion 5 Platform 0 Financial 1

latest quarter score

Earnings Reports

8
Xtant Medical (XTNT) Q2 2026: Biologics Revenue Declines 27% Amid Integration and Product Transition
August 11, 2026
10
Extant Medical (XTNT) Q1 2026: Hemoblast Adds $2B TAM as Portfolio Refocus Drives Guidance Raise
May 13, 2026
14
Extant Medical (XTNT) Q4 2025: Biologics Core Set to Accelerate After $21M Portfolio Divestiture
March 31, 2026
12
XTNT Q3 2025: Licensing Revenue Drives $5.5M Boost as Biologics Expansion Targets Double-Digit Growth
November 11, 2025
20
XTNT Q2 2025: $19M Asset Sale Refocuses Portfolio, Biologics Growth Hits 20%
August 12, 2025
20
Xtant Medical (XTNT) Q1 2025: 18% Revenue Growth Reflects Vertical Integration and Product Innovation Momentum
May 12, 2025
14
Xtant Medical (XTNT) Q4 2024: 28% Annual Revenue Growth Amid Integration and Margin Pressure
March 06, 2025

Browse all companies